Vesicor Therapeutics to go public via a SPAC merger with Black Hawk Acquisition in a $70m deal.

Vesicor Therapeutics, a biotechnology company, to go public via a SPAC merger with Black Hawk Acquisition in a $70m deal. “Our mission is to transform the lives of cancer patients and their families. We are focused on completing preclinical testing in the United States, submitting our IND to the FDA and beginning Phase 1 clinical trials,” Luo Feng, Vesicor Therapeutics Founder and CEO.